NCT04523129: A trial that was reported late by Novaliq GmbH
This trial has reported, although it was 108 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04523129 |
|---|---|
| Title | A Phase 3, Multi-center, Randomized, Double-masked, Vehicle-controlled Clinical Trial to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Dry Eye Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 5, 2020 |
| Completion date | Sept. 3, 2021 |
| Required reporting date | Sept. 3, 2022, midnight |
| Actual reporting date | Dec. 20, 2022 |
| Date last checked at ClinicalTrials.gov | Sept. 16, 2025 |
| Days late | 108 |